Kidney biopsy diagnosis in childhood in the Norwegian Kidney Biopsy Registry and the long-term risk of kidney replacement therapy: a 25-year follow-up.


Journal

Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728

Informations de publication

Date de publication:
04 2023
Historique:
received: 28 04 2022
accepted: 27 07 2022
revised: 16 07 2022
pubmed: 23 8 2022
medline: 16 2 2023
entrez: 22 8 2022
Statut: ppublish

Résumé

There is scarce information on biopsy-verified kidney disease in childhood and its progression to chronic kidney disease stage 5 (CKD 5). This study aims to review biopsy findings in children, and to investigate risk of kidney replacement therapy (KRT). We conducted a retrospective long-term follow-up study of children included in the Norwegian Kidney Biopsy Registry (NKBR) and in the Norwegian Renal Registry (NRR) from 1988 to 2021. In total, 575 children with a median (interquartile range, IQR) age of 10.7 (6.1 to 14.1) years were included, and median follow-up time (IQR) after kidney biopsy was 14.3 (range 8.9 to 21.6) years. The most common biopsy diagnoses were minimal change disease (MCD; n = 92), IgA vasculitis nephritis (IgAVN; n = 76), IgA nephropathy (n = 63), and focal and segmental glomerulosclerosis (FSGS; n = 47). In total, 118 (20.5%) of the biopsied children reached CKD 5, median (IQR) time to KRT 2.3 years (7 months to 8.4 years). Most frequently, nephronophthisis (NPHP; n = 16), FSGS (n = 30), IgA nephropathy (n = 9), and membranoproliferative glomerulonephritis (MPGN; n = 9) led to KRT. The risk of KRT after a kidney biopsy diagnosis is highly dependent on the diagnosis. None of the children with MCD commenced KRT, while 63.8% with FSGS and 100% with NPHP reached KRT. Combining data from kidney biopsy registries with registries on KRT allows for detailed information concerning the risk for later CKD 5 after biopsy-verified kidney disease in childhood. A higher resolution version of the Graphical abstract is available as Supplementary information.

Sections du résumé

BACKGROUND
There is scarce information on biopsy-verified kidney disease in childhood and its progression to chronic kidney disease stage 5 (CKD 5). This study aims to review biopsy findings in children, and to investigate risk of kidney replacement therapy (KRT).
METHODS
We conducted a retrospective long-term follow-up study of children included in the Norwegian Kidney Biopsy Registry (NKBR) and in the Norwegian Renal Registry (NRR) from 1988 to 2021.
RESULTS
In total, 575 children with a median (interquartile range, IQR) age of 10.7 (6.1 to 14.1) years were included, and median follow-up time (IQR) after kidney biopsy was 14.3 (range 8.9 to 21.6) years. The most common biopsy diagnoses were minimal change disease (MCD; n = 92), IgA vasculitis nephritis (IgAVN; n = 76), IgA nephropathy (n = 63), and focal and segmental glomerulosclerosis (FSGS; n = 47). In total, 118 (20.5%) of the biopsied children reached CKD 5, median (IQR) time to KRT 2.3 years (7 months to 8.4 years). Most frequently, nephronophthisis (NPHP; n = 16), FSGS (n = 30), IgA nephropathy (n = 9), and membranoproliferative glomerulonephritis (MPGN; n = 9) led to KRT.
CONCLUSIONS
The risk of KRT after a kidney biopsy diagnosis is highly dependent on the diagnosis. None of the children with MCD commenced KRT, while 63.8% with FSGS and 100% with NPHP reached KRT. Combining data from kidney biopsy registries with registries on KRT allows for detailed information concerning the risk for later CKD 5 after biopsy-verified kidney disease in childhood. A higher resolution version of the Graphical abstract is available as Supplementary information.

Identifiants

pubmed: 35994104
doi: 10.1007/s00467-022-05706-y
pii: 10.1007/s00467-022-05706-y
pmc: PMC9925570
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1249-1256

Informations de copyright

© 2022. The Author(s).

Références

Nephron Clin Pract. 2009;112(3):c199-204
pubmed: 19439991
Kidney Int. 2009 Sep;76(5):546-56
pubmed: 19571790
Pediatr Nephrol. 2013 Mar;28(3):415-26
pubmed: 23052651
Lancet. 2002 Aug 31;360(9334):666-70
pubmed: 12241872
Ren Fail. 2016 Sep;38(8):1228-33
pubmed: 27430296
Nat Rev Nephrol. 2016 Dec;12(12):768-776
pubmed: 27748392
Saudi J Kidney Dis Transpl. 2014 Nov;25(6):1321-7
pubmed: 25394460
Yonsei Med J. 2001 Apr;42(2):247-54
pubmed: 11371115
Pediatr Nephrol. 2016 Mar;31(3):343-8
pubmed: 26884120
Saudi J Kidney Dis Transpl. 2014 May;25(3):680-3
pubmed: 24821178
Pediatr Nephrol. 2013 Jun;28(6):863-74
pubmed: 22829176
BMC Nephrol. 2020 Feb 26;21(1):65
pubmed: 32102663
N Engl J Med. 2013 Jun 20;368(25):2402-14
pubmed: 23782179
J Bras Nefrol. 2013 Jul-Sep;35(3):191-9
pubmed: 24100738
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
J Am Soc Nephrol. 2000 Feb;11(2):319-329
pubmed: 10665939
Kidney Int. 2012 Oct;82(7):790-6
pubmed: 22673888
Am J Nephrol. 2020;51(1):43-53
pubmed: 31822006
Nat Rev Nephrol. 2016 Mar;12(3):133-46
pubmed: 26750453
Ital J Pediatr. 2017 Apr 21;43(1):41
pubmed: 28427453
Nat Rev Dis Primers. 2020 Aug 13;6(1):68
pubmed: 32792490
Front Immunol. 2021 Nov 09;12:771619
pubmed: 34858429
Nat Rev Nephrol. 2014 Oct;10(10):563-73
pubmed: 25072122
J Pediatr. 1995 Dec;127(6):913-9
pubmed: 8523188
Kidney Int. 2011 Oct;80(8):798-801
pubmed: 21960168
Kidney Int. 2018 Mar;93(3):700-705
pubmed: 29329643
Saudi J Kidney Dis Transpl. 2015 Jul-Aug;26(4):810-5
pubmed: 26178566
Clin J Am Soc Nephrol. 2011 Aug;6(8):2034-40
pubmed: 21700827
Pediatr Nephrol. 2006 Sep;21(9):1266-73
pubmed: 16838184
Pediatr Nephrol. 2012 Mar;27(3):363-73
pubmed: 21713524
Pediatr Transplant. 2007 Jun;11(4):366-73
pubmed: 17493215
J Nephrol. 2009 Nov-Dec;22(6):739-46
pubmed: 19967653
Kidney Dis (Basel). 2018 Feb;4(1):10-19
pubmed: 29594138
Clin J Am Soc Nephrol. 2012 Oct;7(10):1591-7
pubmed: 22837269
Kidney360. 2021 May 28;2(8):1339-1348
pubmed: 35369654
Pediatr Nephrol. 1994 Feb;8(1):15-20
pubmed: 8142218
Lancet. 1992 Feb 1;339(8788):280-2
pubmed: 1346291
Nephrol Dial Transplant. 1998 Feb;13(2):293-7
pubmed: 9509437
J Pediatr. 1985 Jan;106(1):27-32
pubmed: 2981307
J Clin Med. 2021 May 25;10(11):
pubmed: 34070665

Auteurs

Ann Christin Gjerstad (AC)

Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway. ancgje@ous-hf.no.

Rannveig Skrunes (R)

Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Camilla Tøndel (C)

Department of Clinical Science, University of Bergen, Bergen, Norway.
Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.

Anders Åsberg (A)

The Norwegian Renal Registry, Oslo University Hospital - Rikshospitalet, Oslo, Norway.
Department of Transplantation Medicine, Oslo University Hospital - Rikshospitalet, Oslo, Norway.
Department of Pharmacy, University of Oslo, Oslo, Norway.

Sabine Leh (S)

Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Department of Pathology, Haukeland University Hospital, Bergen, Norway.

Claus Klingenberg (C)

Department of Pediatrics and Adolescence Medicine, University Hospital of North Norway, Tromsø, Norway.
Paediatric Research Group, Faculty of Health Sciences, UiT-The Arctic University of Norway, Tromsø, Norway.

Henrik Døllner (H)

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Children's Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.

Clara Hammarstrøm (C)

Department of Pathology, Oslo University Hospital - Rikshospitalet, Oslo, Norway.

Anna Kristina Bjerre (AK)

Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH